Sign in

ENDV on OTC

ENDONOVO THERAPEUTICS, INC.

ENDONOVO THERAPEUTICS, INC. is an American electromedical and electrotherapeutic apparatus company.2 It is headquartered in Los Angeles, United States.2 Its shares trade on OTC under the symbol ENDV.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Nexalin Technology, Inc., POSITRON CORP or iTonic Holdings Ltd, or pick any stock.

  • TickerENDV on OTC2
  • IndustryElectromedical & Electrotherapeutic Apparatus2
  • HeadquartersLos Angeles, United States2
  • Incorporated inDE3
  • Business address6320 Canoga Avenue, 15Th Floor, Woodland Hills, Ca 913673
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KCSDK8HM68VH232
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49882172

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

92.6%Gross margin4
-2411.7%Operating margin4
-13649.2%Net margin4
85.2%Revenue growth, 20224

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue7¢$10.0K
  • Other costs93¢$125.4K

Out of $135.4K in revenue.4 The company lost money this year.

Financial statements

Revenue5674$135.4K in 2022+63% since 2018
0$100.0K$200.0K$300.0K$400.0K2018: $83.3K$83.3K20182019: $310.2K$310.2K2019+273%2020: $165.8K$165.8K2020−47%2021: $73.1K$73.1K2021−56%2022: $135.4K$135.4K2022+85%
Gross profit5674$125.4K in 2022+78% since 2018
0$100.0K$200.0K$300.0K2018: $70.3K$70.3K20182019: $216.8K$216.8K2019+208%2020: $100.4K$100.4K2020−54%2021: $58.1K$58.1K2021−42%2022: $125.4K$125.4K2022+116%
Operating income895674-$3.3M in 2022−40% since 2016
-$6.0M-$4.0M-$2.0M02016: -$5.4M-$5.4M20162017: -$4.6M-$4.6M2017−15%2018: -$4.2M-$4.2M2018−10%2019: -$3.8M-$3.8M2019−8%2020: -$2.9M-$2.9M2020−24%2021: -$2.2M-$2.2M2021−24%2022: -$3.3M-$3.3M2022+47%
Net income895674-$18.5M in 2022+248% since 2016
-$20.0M-$15.0M-$10.0M-$5.0M02016: -$5.3M-$5.3M20162017: -$10.8M-$10.8M2017+103%2018: -$6.4M-$6.4M2018−40%2019: -$17.3M-$17.3M2019+169%2020: -$395.6K-$395.6K2020−98%2021: -$3.1M-$3.1M2021+685%2022: -$18.5M-$18.5M2022+495%
Fiscal year2016201720182019202020212022
Revenue$83.3K5$310.2K6$165.8K7$73.1K4$135.4K4
Cost of revenue$12.9K5$93.4K6$65.4K7$15.0K4$10.0K4
Gross profit$70.3K5$216.8K6$100.4K7$58.1K4$125.4K4
Research and development$08$115.2K9$274.3K5$153.1K6$3.3K7$07
Operating expenses$2.3M4$3.4M4
Operating income-$5.4M8-$4.6M9-$4.2M5-$3.8M6-$2.9M7-$2.2M4-$3.3M4
Interest$2.1M7$941.6K7
Income before tax-$3.1M4-$18.5M4
Income tax
Net income-$5.3M8-$10.8M9-$6.4M5-$17.3M6-$395.6K7-$3.1M4-$18.5M4
Earnings per share-$0.054-$0.134
Shares (weighted, basic)59.8M shares4139.2M shares4

Compare ENDONOVO THERAPEUTICS, INC. with another company

What it owns

What ENDONOVO THERAPEUTICS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$85.9K7 Dec 31, 2021$13.4K7 Dec 31, 2020+540.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$3.2M4 Dec 31, 2022$2.6M4 Dec 31, 2021+25.0%
Finite-lived intangibles, net$1.3M4 Dec 31, 2022$1.9M4 Dec 31, 2021−33.8%
Patents, net$4.5M4 Dec 31, 2022$4.5M4 Dec 31, 20210%

Leadership

Who has led ENDONOVO THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alan Brian Collier2015–2020
20202025
Board members and other officers (1)

Former names

  • Hanover Portfolio Acquisitions, Inc.Sep 22, 2011 to Jan 24, 20143

Timeline

  1. Jan 3, 20248-K Entered a material agreement14
  2. Dec 4, 20238-K Entered a material agreement15
  3. Oct 12, 20238-K Other events16
  4. Mar 29, 20238-K Entered a material agreement17
  5. Sep 27, 20228-K Entered a material agreement18
  6. Jun 26, 2015New chief executive Alan Brian Collier becomes CEO13
  7. May 26, 2011Founded ENDONOVO THERAPEUTICS, INC. is founded2

Filings

30 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 5 major events, 15 other. The latest 20:

  1. Sep 19, 2024SEC STAFF ACTION EDGAR
  2. Feb 2, 202415-12G EDGAR
  3. Jan 3, 20248-K EDGAR
  4. Dec 29, 202310-Q/A EDGAR
  5. Dec 29, 202310-Q EDGAR
  6. Dec 4, 20238-K EDGAR
  7. Nov 15, 2023NT 10-Q EDGAR
  8. Oct 12, 20238-K EDGAR
  9. Aug 25, 20231-A/A EDGAR
  10. Aug 21, 202310-Q EDGAR
  11. Aug 15, 2023NT 10-Q EDGAR
  12. Jun 14, 20231-A/A EDGAR
  13. May 22, 202310-Q EDGAR
  14. May 16, 2023NT 10-Q EDGAR
  15. Apr 17, 202310-K EDGAR
  16. Mar 31, 2023NT 10-K EDGAR
  17. Mar 29, 20238-K EDGAR
  18. Nov 21, 202210-Q EDGAR
  19. Nov 14, 2022NT 10-Q EDGAR
  20. Sep 27, 20228-K EDGAR

The 30 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How ENDONOVO THERAPEUTICS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARENDONOVO THERAPEUTICS, INC.1
  • CIK0001528172
  • Employer ID (EIN)45-25525281
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address6320 Canoga Avenue, 15Th Floor, Woodland Hills, CA 913671
  • Phone(800) 489-47741
  • Shares outstanding318,751,597 as of Dec 28, 202311
  • Public float$1.1M as of Jun 30, 20224
  • On EDGAR sinceSep 22, 20111
  • Filings502 in all: 4 (297), 10-Q (36), 8-K (31), NT 10-Q (25), 10-K (13), NT 10-K (12), CORRESP (8), EFFECT (8)1
    All 32 form types

    D (7), S-1/A (7), UPLOAD (7), 10-Q/A (6), 4/A (6), S-1 (5), 1-A/A (3), 10-K/A (3), 3 (3), 424B3 (3), DEF 14C (3), PRE 14C (3), D/A (2), POS AM (2), RW (2), SC 13G (2), 1-A (1), 15-12G (1), 8-A12G (1), 8-K/A (1), DEF 14A (1), NT 10-Q/A (1), RW WD (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Apr 17, 2023
    Quarterly report (10-Q) Dec 29, 2023
    Proxy statement (DEF 14A) Nov 14, 2019
    Latest 8-K (8-K) Jan 3, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
  18. 18